Generation Bio Inc. (GBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
GBIO Stock Price Chart Interactive Chart >
GBIO Price/Volume Stats
| Current price | $27.18 | 52-week high | $55.72 |
| Prev. close | $26.60 | 52-week low | $19.16 |
| Day low | $25.87 | Volume | 186,728 |
| Day high | $27.32 | Avg. volume | 470,448 |
| 50-day MA | $23.46 | Dividend yield | N/A |
| 200-day MA | $29.75 | Market Cap | 1.54B |
Generation Bio Inc. (GBIO) Company Bio
Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Latest GBIO News From Around the Web
Below are the latest news stories about Generation Bio Co that investors may wish to consider to help them evaluate GBIO as an investment opportunity.
Generation Bio Reports Business Highlights and Second Quarter 2021 Financial ResultsCAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and second quarter 2021 financial results. “This quarter we announced our shift to rapid enzymatic synthesis, or RES, for production of our closed-ended DNA, ceDNA, constructs and our signing of a lease to establish significant internal current Good Manufacturing Practice |
Generation Bio to Present at Wedbush PacGrow Healthcare Conference 2021CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a panel discussion at the Wedbush PacGrow Healthcare Conference 2021 on Tuesday, August 10 at 9:10 a.m. ET. A live webcast of the panel will be available on the investor section of the company’s website at |
Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline UpdateCompany to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing Lease agreement signed to build an in-house RES manufacturing facility providing cGMP capacity for and internal control over clinical and initial commercial supply IND submission for hemophilia A now planned for 2023; factor VIII expression data with RES material in non-human primates expected year-end 2021 CAMBRIDGE, Mass., July 14, 2021 ( |
Generation Bio to Present at William Blair Biotech Focus ConferenceCAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, at 9:00 a.m. ET. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A rep |
Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
GBIO Price Returns
| 1-mo | 14.06% |
| 3-mo | 11.67% |
| 6-mo | -20.29% |
| 1-year | -8.98% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -4.13% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...